Literature DB >> 24631102

Infectious outcomes of nephrostomy drainage before percutaneous nephrolithotomy compared to concurrent access.

Aaron D Benson1, Trisha M Juliano1, Nicole L Miller2.   

Abstract

PURPOSE: We hypothesized that establishing percutaneous nephrostomy drainage and treating with renal urine culture specific antibiotics would lead to a decreased sepsis rate in patients at increased risk for infection. We analyzed the experience of a single surgeon with sepsis after percutaneous nephrolithotomy following prior nephrostomy drainage compared to percutaneous nephrolithotomy with concurrent percutaneous renal collecting system access.
MATERIALS AND METHODS: We retrospectively reviewed the records of patients who underwent percutaneous nephrolithotomy. Pertinent collected data included patient infection history, preoperative urine cultures, renal calculi burden size, renal urine/stone cultures, length of stay and sepsis/systemic inflammatory response syndrome events.
RESULTS: Percutaneous nephrolithotomy was performed in 219 patients between September 2007 and June 2012. Of the patients 67 (30.6%) had preplaced nephrostomy drainage (group 1) while 152 (69.4%) had concurrent percutaneous renal access (group 2). Stone culture was positive more often in group 1 than in group 2 (64.2% vs 25.7%, p = 0.0001). The concordance rate of preoperative renal urine culture results with stone culture results was higher than the concordance rates of lower urinary tract urine culture results in groups 1 and 2 (30.6% vs 21.4% and 7.3%, respectively). There was no systemic inflammatory response syndrome/sepsis episode in group 1 but we noted a 5.9% systemic inflammatory response syndrome/sepsis rate in group 2 (p = 0.043).
CONCLUSIONS: In this retrospective study our data suggest that in patients at high risk for urosepsis preoperative nephrostomy drainage with renal urine culture and culture specific antibiotic treatment may decrease the risk of postoperative infectious complications. Stone culture is also important since many patients at high risk for infection will have positive stone cultures. A prospective study is needed to confirm these retrospective data findings.
Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  infection; kidney; nephrolithiasis; nephrostomy; percutaneous; postoperative complications

Mesh:

Year:  2014        PMID: 24631102     DOI: 10.1016/j.juro.2014.03.004

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  Percutaneous nephrolithotomy: complications and how to deal with them.

Authors:  Daniel A Wollin; Glenn M Preminger
Journal:  Urolithiasis       Date:  2017-11-17       Impact factor: 3.436

2.  Renal pelvis urine Gram stain as a traditional, but new marker in predicting postoperative fever and stone culture positivity in percutaneous nephrolithotomy: an observational, prospective, non-randomized cohort study.

Authors:  Nejdet Karsiyakali; Ugur Yucetas; Aysel Karatas; Emre Karabay; Emrah Okucu; Erkan Erkan
Journal:  World J Urol       Date:  2020-07-28       Impact factor: 4.226

3.  The impact of nephrostomy drainage prior to mini-percutaneous nephrolithotomy in patients with ESBL-positive Escherichia coli.

Authors:  Zhijian Zhao; Wenqi Wu; Tao Zeng; Xiangkun Wu; Yongda Liu; Guohua Zeng
Journal:  World J Urol       Date:  2020-03-20       Impact factor: 4.226

4.  Heart of Darkness.

Authors:  Peter Alken
Journal:  J Endourol Case Rep       Date:  2016-11-01

5.  Percutaneous nephrolithotomy in octogenarians and beyond: How old is too old?

Authors:  Bradley Morganstern; Riccardo Galli; Piruz Motamedinia; David Leavitt; Mohamed Keheila; Eric Ghiraldi; David Hoenig; Arthur Smith; Zeph Okeke
Journal:  Asian J Urol       Date:  2015-09-04

Review 6.  Contemporary best practice in the management of staghorn calculi.

Authors:  Adam Sharbaugh; Tara Morgan Nikonow; Gregory Kunkel; Michelle Jo Semins
Journal:  Ther Adv Urol       Date:  2019-05-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.